Results 41 to 50 of about 15,755 (201)

Epigenetic regulation of CD38/CD48 by KDM6A mediates NK cell response in multiple myeloma

Nature Communications
Anti-CD38 monoclonal antibodies like Daratumumab (Dara) are effective in multiple myeloma (MM); however, drug resistance ultimately occurs and the mechanisms behind this are poorly understood.
Jiye Liu, Lijie Xing, Jiang Li, Kenneth Wen, Ning Liu, Yuntong Liu, Gongwei Wu, Su Wang, Daisuke Ogiya, Tian-Yu Song, Keiji Kurata, Johany Penailillo, Eugenio Morelli, Tingjian Wang, Xiaoning Hong, Annamaria Gulla, Yu-Tzu Tai, Nikhil Munshi, Paul Richardson, Ruben Carrasco, Teru Hideshima, Kenneth C. Anderson   +21 more
doaj   +1 more source

ARQ-197, a small-molecule inhibitor of c-Met, reduces tumour burden and prevents myeloma-induced bone disease in vivo [PDF]

, 2018
The receptor tyrosine kinase c-Met, its ligand HGF, and components of the downstream signalling pathway, have all been implicated in the pathogenesis of myeloma, both as modulators of plasma cell proliferation and as agents driving osteoclast ...
Buckle, C.H., Chantry, A.D., Down, J.M., Evans, H.R., Fisher, M., Lath, D.L., Lawson, M.A.   +6 more
core   +2 more sources

The Role of Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma With Renal Impairment: A Systematic Review

American Journal of Hematology, EarlyView.
ABSTRACT Renal impairment (RI), defined as estimated glomerular filtration rate less than 60 mL/min with or without the need for dialysis, is a frequent and severe complication in patients with relapsed/refractory multiple myeloma (RRMM), as it can affect patient prognosis, drug metabolism and treatment options.
Ioannis Ntanasis‐Stathopoulos, Sotirios Manganas, Charalampos Filippatos, Konstantinos Karamouzis, Maria Gavriatopoulou, Efstathios Kastritis, Evangelos Terpos, Meletios‐Athanasios Dimopoulos   +7 more
wiley   +1 more source

Daratumumab for treatment‐refractory antibody‐mediated diseases in neurology [PDF]

, 2022
Background and purpose A fraction of patients with antibody-mediated autoimmune diseases remain unresponsive to first-/second-line and sometimes even to escalation immunotherapies.
Alexander, Tobias, Aschman, Tom, Blau, Igor‐Wolfgang, Hoffmann, Sarah, Meisel, Andreas, Meisel, Christian, Ostendorf, Lennard, Prüss, Harald, Radbruch, Helena, Scheibe, Franziska   +9 more
core   +1 more source

Affinity Peptides With pH Sensitivity for the Enrichment of CD38+ Cells

Biotechnology and Bioengineering, EarlyView.
ABSTRACT The selective enrichment of cell populations based on surface markers is critical for the advancement of gene and cell therapies. Current antibody‐based cell isolation methods, such as fluorescence‐ and magnetic‐activated cell sorting (FACS and MACS), offer high specificity but are limited by scalability, cost, and potential adverse effects on
Gabrielle Rusch, Mickael Meyer, I. Mohamed Irfan, Carson Huber, Joseph Burclaff, Scott T. Magness, Stefano Menegatti, Michael Daniele   +7 more
wiley   +1 more source

Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma

Journal of Hematology & Oncology, 2016
Daratumumab is a human monoclonal antibody that targets CD38, a cell surface protein that is overexpressed on multiple myeloma (MM) cells. Preclinical studies have shown that daratumumab induces MM cell death through several mechanisms, including ...
Larysa Sanchez, Yucai Wang, David S. Siegel, Michael L. Wang   +3 more
doaj   +1 more source

Nuevos usos de la talidomida: Del desastre a la esperanza [PDF]

, 2017
Trabajo fin de grado en EnfermeríaLa talidomida se mantiene como uno de los medicamentos más controvertidos históricamente debido a que provocó a nivel mundial numerosos casos de embriopatías en los niños durante la década de los 60.
Williams Aguirre, Ana
core  

Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment [PDF]

, 2016
With contemporary therapeutic strategies in multiple myeloma, heretofore unseen depth and rate of responses are being achieved. These strategies have paralleled improvements in outcome of multiple myeloma patients.
Jinming Song, Kenneth H. Shain, Taiga Nishihori   +2 more
core   +1 more source

Systemic anti‐cancer therapy associated with the occurrence of peripheral neurotoxicity and, specifically, peripheral neuropathy

International Journal of Cancer, EarlyView.
What's New? While the effectiveness of systemic anticancer therapy is well documented, it commonly causes severe toxicity. This study of the 467 systemic anticancer therapy agents currently approved globally for clinical and/or research purposes found that peripheral neurotoxicity is associated with 45% of classical chemotherapies, 21% of targeted ...
Cassie Higgins, Lynn R. Gauthier, Blair H. Smith, Lesley Colvin   +3 more
wiley   +1 more source

Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland [PDF]

, 2015
The availability of drugs such as thalidomide, bortezomib and lenalidomide changed the landscape in myeloma treatment and has extended the median survival up to 10 years with a substantial improvement in quality of life. This development prompted a Swiss
Bargetzi, M., Betticher, D.C., Duchosal, M.A., Heim, D., Hess, U., Ketterer, N., Lerch, E., Matthes, T., Mey, U., Pabst, T., Renner, C., Samaras, P., Taverna, C., Zander, T.   +13 more
core   +4 more sources